We are excited to announce that PharmaDJ, a leading trade media publishing house and consulting firm, and the Chinese Antibody Society will continue to collaborate to provide comprehensive analysis and reports about therapeutic antibody licensing deals between Chinese biopharma and overseas companies. This is our second business report for 2021, and we will focus on the licensing deals from H2 2021. For a detailed summary of antibody licensing deals closed in H1 2021 in China, please read our first business report.

Fourty antibody deals were closed at a total value of ~ $14.7 billion in 2021. Twenty two of them were in-licensing deals; eighteen were out-licensing deals. Among all the assets involved, sixteen assets were in the pre-clinical stage, sixteen programs were in clinical development, and six programs were approved products.

For more details of the analysis and reports, please see the published post in Officitial WeChat Account of Chinese Antibody Society.